Brain Device Helps Many Children With Hard-To-Treat Epilepsy

What was studied

This study combined results from 39 published studies on responsive neurostimulation (RNS) in children and teens age 18 or younger with drug-resistant epilepsy. In total, 413 patients were included. Most studies were retrospective, and one study was prospective. The typical study was small, with a median of 7 patients, and the median follow-up time was about 18.7 months.

The review examined how often RNS was associated with seizure reduction, how often children became seizure-free, what adverse events were reported, and whether quality of life, cognition, or behavior changed. The authors also examined whether age, length of follow-up, generalized epilepsy, or thalamic lead placement were associated with seizure outcomes.

What they found

About 64.8% of patients had at least a 50% reduction in seizures. About 28.4% had at least a 90% reduction. Seizure freedom was uncommon, at 2.9%.

The pooled adverse event rate was 15.8%. The most common device-related adverse event was infection, affecting about 4% of patients. In the 12 studies that reported non-seizure outcomes, quality of life, cognition, and behavior were generally stable or improved.

Longer follow-up was the only factor associated with seizure freedom on meta-regression. Mean age, epilepsy type, and thalamic lead placement were not significant predictors of seizure freedom, and no predictors were identified for responder or super-responder outcomes.

Limits of the evidence

The evidence has important limits. Most included studies were retrospective and small. Publication bias was also detected, which means studies with more favorable results may have been more likely to be published.

Median follow-up was 18.7 months, so longer-term results remain uncertain. Seizure freedom was rare, and non-seizure outcomes such as quality of life and cognition were reported in only 12 studies, so those findings are less certain. The review also assessed risk of bias and certainty of evidence, but the abstract does not provide those detailed results.

For families and caregivers

For families, this review suggests that RNS may be associated with fewer seizures in many children with hard-to-treat epilepsy, but complete seizure freedom was uncommon. The safety profile appeared manageable overall in the included studies, though device-related problems such as infection were reported.

This may be relevant when families are discussing treatment options after medicines have not worked, especially in specialized epilepsy care. The results support selective off-label use in children, but the evidence is still limited and longer-term prospective data are needed.

What to watch next

Larger prospective, multicenter studies with longer follow-up and more consistent reporting of quality of life, cognition, and behavior would help strengthen the evidence base.

Terms in this summary

drug-resistant epilepsy

Epilepsy that does not come under good control after trying appropriate seizure medicines.

responsive neurostimulation (RNS)

A device that monitors brain activity and sends small electrical pulses when it detects patterns that may lead to a seizure.

systematic review

A study that collects and carefully reviews all relevant research on a question.

meta-analysis

A method that combines results from multiple studies to estimate an overall result.

seizure responder rate

The percentage of patients who had at least a 50% reduction in seizures.

seizure freedom

Having no seizures during the measured follow-up period.

super-responder

A patient who had a very large seizure reduction, usually at least 90%.

thalamic lead placement

Positioning the device wires in the thalamus, a deep part of the brain involved in seizure networks.